Le Lézard
Classified in: Health
Subject: PDT

Takara Bio Announces Launch of Beta Cell Differentiation Service

MOUNTAIN VIEW, Calif., May 17, 2018 /PRNewswire/ -- The Takara Bio Group, the leading provider of human stem cell differentiation services globally, has launched the Cellartis® Directed Differentiation to Beta Cells Service for the delivery of high-quality, custom human induced pluripotent stem cell (hiPSC)-derived beta cells for diabetes research and metabolic disease modeling.

Takara Bio, Inc., Contributing to the health of humankind through the development of revolutionary biotechnologies such as gene therapy.

The gold standard in this field involves the use of primary islets of Langerhans, which are difficult and costly to obtain. Islets containing insulin-secreting beta cells come from donors with different genetic backgrounds, confounding results by adding variability to cellular models and assays. The new differentiation service complements an existing suite of stem cell services and provides a reliable and plentiful source of mature beta cells from customer-specified hiPSCs, enabling beta cell functional studies, diabetes modeling, and compound screening for insulin secretion and regulation.

Catharina Brandsten, Director R&D at Takara Bio Europe AB, said, "Compared with human primary pancreatic islet beta cells, iPS-derived beta cells provide better access to cells and reduced batch-to-batch variability, providing reproducible and biologically relevant data. Our standardized method mimics embryonic development to manufacture large quantities of cryopreserved beta cells that secrete insulin and C-peptide, making the cells an excellent research tool for disease modeling and drug discovery."

About Takara Bio
The Takara Bio Group of companies is committed to improving the human condition through biotechnology. It is led by Takara Bio Inc. which represents the biomedical business interests of its parent company, Takara Holdings Inc. The Takara Bio companies support the life science market through the Takara, Clontech, and Cellartis brands, with the Cellartis brand focusing on stem cell-derived products and services for drug discovery, disease modeling, and applications within regenerative medicine. Learn more about Takara Bio at takara-bio.com (Japanese) and takarabio.com (English).


SOURCE Takara Bio Group

These press releases may also interest you

at 14:23
Bid Doc, Inc., developers of the BidMySmile platform, a digital marketplace that connects qualified patients with orthodontic specialists, announced this week that it has closed a seed-round of equity financing. This transaction represents the...

at 14:19
New Zealand decision automation software company dominates in global competition to recognise most commercially successful application of business rules IDIOM, a New Zealand decision automation software company has been named the winner of two...

at 14:02
Skyview Ventures http://www.skyviewcapital.com/home/ventures/, the early and growth stage investment arm of global private investment firm Skyview Capital, LLC, has completed its seed round investment in Pr3vent, Inc. ("Pr3vent").  Pr3vent is a Palo...

at 14:00
CVS Health announced today that it is embarking on a pilot project in the Tri-Cities area of Atlanta, Georgia, aimed at addressing diabetes in medically underserved communities with chronically high rates of this disease.  In collaboration with...

at 13:57
Brent Smith and Zach Myers from the multi-platinum rock band Shinedown will join the DC101's One More Light walk team at the 12th Annual Washington, D.C. Out of the Darkness Community Walk to benefit the American Foundation for Suicide Prevention...

at 13:45
What it means to be healthy is often under debate. People don't want to be labeled as unhealthy and can get rather defensive when those around them start describing their lifestyle as essentially being bad. Financial Education Benefits Center (FEBC),...

News published on 17 may 2018 at 08:00 and distributed by: